InterventionsHuman trial

Effect of Subcutaneous Semaglutide on Cardiorenal Outcomes across Type 2 Diabetes Subtypes: SUSTAIN 6 Post Hoc Analysis

ADA Scientific Sessions 2026 Abstract

The paper

WANG W, ZHANG J, DONG B et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1775-P

doi.org/10.2337/db26-1775-p

Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026